Chronobiological hypothalamic-pituitary-thyroid axis status and antidepressant outcome in major depression

Psychoneuroendocrinology

Volumn 59, Issue , 2015, Pages 71-80

  Duval, Fabrice ^a   Mokrani, Marie Claude ^a   Erb, Alexis ^a   Gonzalez Lopera, Felix ^a   Alexa, Claudia ^a   Proudnikova, Xenia ^a   Butucaru, Iuliana ^a  

^a Centre Hospitalier de Rouffach   (France)

Author keywords

Antidepressant treatment outcome; Depression; Hypothalamic pituitary thyroid (HPT) axis; Thyroid hormones; Thyrotropin (TSH); Thyrotropin releasing hormone (TRH) test

Indexed keywords

AGOMELATINE; ALIMEMAZINE; ANTIDEPRESSANT AGENT; DEXAMETHASONE; ESCITALOPRAM; LIOTHYRONINE; PROTIRELIN; THYROTROPIN; THYROXINE; TIANEPTINE; VENLAFAXINE;

ADULT; ARTICLE; CHRONOBIOLOGY; CLINICAL ARTICLE; CONTROLLED STUDY; DEXAMETHASONE SUPPRESSION TEST; DISEASE RESISTANCE; DRUG CHOICE; DRUG DOSE INCREASE; DRUG EFFICACY; DSM-IV; EUTHYROIDISM; FEMALE; FREE LIOTHYRONINE INDEX; FREE THYROXINE INDEX; HAMILTON DEPRESSION RATING SCALE; HUMAN; HYPOTHALAMUS HYPOPHYSIS THYROID SYSTEM; MAJOR DEPRESSION; MALE; NORMAL VALUE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROGNOSIS; PROTIRELIN TEST; RECOMMENDED DRUG DOSE; REMISSION; SLEEP DISORDER; THYROTROPIN BLOOD LEVEL; TREATMENT DURATION; TREATMENT RESPONSE; BLOOD; CASE CONTROL STUDY; DEPRESSIVE DISORDER, MAJOR; DRUG EFFECTS; HYPOPHYSIS ADRENAL SYSTEM; HYPOTHALAMUS HYPOPHYSIS SYSTEM; METABOLISM; MIDDLE AGED; PREDICTIVE VALUE; TREATMENT OUTCOME;

ADULT; ANTIDEPRESSIVE AGENTS; CASE-CONTROL STUDIES; CHRONOBIOLOGY PHENOMENA; DEPRESSIVE DISORDER, MAJOR; FEMALE; HUMANS; HYPOTHALAMO-HYPOPHYSEAL SYSTEM; MALE; MIDDLE AGED; PITUITARY-ADRENAL SYSTEM; PREDICTIVE VALUE OF TESTS; THYROTROPIN; THYROTROPIN-RELEASING HORMONE; TREATMENT OUTCOME;

EID: 84937467765     PISSN: 03064530     EISSN: 18733360     Source Type: Journal    
DOI: 10.1016/j.psyneuen.2015.05.005     Document Type: Article

References (51)

1. Aizawa S., Hoshino S., Sakata I., Adachi A., Yashima S., Hattori A., Sakai T. Diurnal change of thyroid-stimulating hormone mRNA expression in the rat pars tuberalis. J. Neuroendocrinol. 2007, 19:839-846.
2. Alkemade A., Unmehopa U.A., Brouwer J.P., Hoogendijk W.J., Wiersinga W.M., Swaab D.F., Fliers E. Decreased thyrotropin-releasing hormone gene expression in the hypothalamic paraventricular nucleus of patients with major depression. Mol. Psychiatry 2003, 8:838-839.
3. Alkemade A., Unmehopa U.A., Wiersinga W.M., Swaab D.F., Fliers E. Glucocorticoids decrease thyrotropin-releasing hormone messenger ribonucleic acid expression in the paraventricular nucleus of the human hypothalamus. J. Clin. Endocrinol. Metab. 2005, 90:323-327.
4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 1994, 317-391. American Psychiatric Press, Washington. 4th ed.
5. Atterwill C.K., Catto L.C., Heal D.J., Holland C.W., Dickens T.A., Jones C.A. The effects of desipramine (DMI) and electroconvulsive shock (ECS) on the function of the hypothalamo-pituitary-thyroid axis in the rat. Psychoneuroendocrinology 1989, 14:339-346.
6. Bartalena L., Placidi G.F., Martino E., Falcone M., Pellegrini L., Dell'Osso L., Pacchiarotti A., Pinchera A. Nocturnal serum thyrotropin (TSH) surge and the TSH response to TSH-releasing hormone: dissociated behavior in untreated depressives. J. Clin. Endocrinol. Metab. 1990, 71:650-655.
7. Bauer M., Pfennig A., Severus E., Whybrow P.C., Angst J., Möller H.J. World Federation of Societies of Biological Psychiatry. Task force on unipolar depressive disorders. World J. Biol. Psychiatry 2013, 14:334-385.
8. Benedetti F. Antidepressant chronotherapeutics for bipolar depression. Dialogues Clin. Neurosci. 2012, 14:401-411.
9. Bennett G.W., Green A.R., Lighton C., Marsden C.A. Changes in the behavioural response to a TRH analogue following chronic amitriptyline treatment and repeated electroconvulsive shock in the rat. Br. J. Pharmacol. 1986, 88:129-139.
10. Blier P. Neurotransmitter targeting in the treatment of depression. J. Clin. Psychiatry 2013, 74:19-24.
11. Bourin M., David D.J., Jolliet P., Gardier A. Mechanism of action of antidepressants and therapeutic perspectives. Therapie 2002, 57:385-396.
12. Carroll B.J., Feinberg M., Greden J.F., Tarika J., Albala A.A., Haskett R.F., James N.M., Kronfol Z., Lohr N., Steiner M., de Vigne J.P., Young E. A specific laboratory test for the diagnosis of melancholia. Standardization, validation, and clinical utility. Arch. Gen. Psychiatry 1981, 8:15-22.
13. Carvalho A.F., Cavalcante J.L., Castelo M.S., Castelo M.S., Lima M.C. Augmentation strategies for treatment resistant depression: a literature review. J. Clin. Pharm. Ther. 2007, 32:415-428.
14. Coplan J.D., Gopinath S., Abdallah C.G., Berry B.R. A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy. Front. Behav. Neurosci. 2014, 8(189):1-16.
15. Dunlop B.W., Mayberg H.S. Neuroimaging-based biomarkers for treatment selection in major depressive disorder. Dialogues Clin. Neurosci. 2014, 16:479-490.
16. Duval F., Macher J.P., Mokrani M.C. Difference between evening and morning thyrotropin response to protirelin in major depressive episode. Arch. Gen. Psychiatry 1990, 47:443-448.
17. Duval F., Mokrani M.C., Crocq M.A., Bailey P., Macher J.P. Influence of thyroid hormones on morning and evening TSH response to TRH in major depression. Biol. Psychiatry 1994, 35:926-934.
18. Duval F., Mokrani M.C., Crocq M.A., Jautz M., Bailey P.E., Diep T.S., Macher J.P. Effect of antidepressant medication on morning and evening thyroid function tests during a major depressive episode. Arch. Gen. Psychiatry 1996, 53:833-840.
19. Duval F., Mokrani M.C., Bailey P., Correa H., Diep T.S., Crocq M.A., Macher J.P. Thyroid axis activity and serotonin function in major depressive episode. Psychoneuroendocrinology 1999, 24:695-712.
20. Duval F., Monreal J., Mokrani M.C., Crocq M.A., Macher J.P. Effect of antidepressant medication on responses to TRH and apomorphine tests in depression. Biol. Psychiatry 2002, 51:123.
21. Duval F., Mokrani M.C., Lopera F.G., Diep T.S., Rabia H., Fattah S. Thyroid axis activity and suicidal behavior in depressed patients. Psychoneuroendocrinology 2010, 35:1045-1054.
22. Duval F., Mokrani M.C., Gonzalez Lopera F., Alexa C., Rabia H., Proudnikova X., Erb A. Difference between morning and evening thyrotropin response to protirelin (TRH) and prediction of antidepressant treatment outcome in major depression. Hormones and Behavior 2013, 85-103. Nova Science Publishers, New York. N. Gotsiridze-Columbus (Ed.).
23. Endicott J., Andreasen N., Spitzer R.L. Family History-Research Diagnostic Criteria 1978, Research Assessment and Training Unit, New York State Psychiatric Institute, NewYork.
24. Eravci M., Pinna G., Meinhold H., Baumgartner A. Effects of pharmacological and nonpharmacological treatments on thyroid hormone metabolism and concentrations in rat brain. Endocrinology 2000, 141:1027-1040.
25. Frank E., Prien R.F., Jarrett R.B., Keller M.B., Kupfer D.J., Lavori P.W., Rush J., Weissman M.M. Conceptualization and rationale for consensus definitions of terms in major depressive disorder. Arch. Gen. Psychiatry 1991, 48:851-855.
26. Gambi F., De Berardis D., Sepede G., Campanella D., Galliani N., Carano A., La Rovere L., Salini G., Penna L., Cicconetti A., Spinella S., Quartesan R., Salerno R.M., Ferro F.M. Effect of mirtazapine on thyroid hormones in adult patients with major depression. Int. J. Immunopathol. Pharmacol. 2005, 18:737-744.
27. Gendall K.A., Joyce P.R., Mulder R.T., Luty S.E. Thyroid indices and response to fluoxetine and nortriptyline in major depression. J. Psychopharmacol. 2003, 17:431-437.
28. Grady M.M., Stahl S.M. Novel agents in development for the treatment of depression. CNS Spectr. 2013, 18:37-40.
29. Hamilton M. A rating scale for depression. J. Neurol. Neurosurg. Psychiatry 1960, 23:56-62.
30. Ising M., Holsboer F. Biomarkers for the development of antidepressant and anxiolytic drugs. Biomarkers for Psychiatric Disorders 2008, 427-443. Springer Science+Business Media, LLC, New York. C.W. Turck (Ed.).
31. Jackson I.M. The thyroid axis and depression. Thyroid 1998, 8:951-956.
32. Joffe R.T., Levitt A.J. The thyroid and depression. The Thyroid Axis and Psychiatric Illness 1993, 195-253. American Psychiatric Press, Washington. R.T. Joffe, A.J. Levitt (Eds.).
33. Kennedy J.A., Jarrett D.B., Wellby M.L. Influence of imipramine on the hypothalamic/pituitary/thyroid axis of the rat. Metabolism 1997, 46:1429-1434.
34. Kraemer H.C., Frank E., Kupfer D.J. Moderators of treatment outcomes: clinical, research, and policy importance. JAMA 2006, 296:1286-1289.
35. Krauchi K., Cajochen C., Mori D., Graw P., Wirz-Justice A. Early evening melatonin and S-20098 advance circadian phase and nocturnal regulation of core body temperature. Am. J. Physiol. 1997, 272:1178-1188.
36. Leuchter A.F., Cook I.A., Marangell L.B., Gilmer W.S., Burgoyne K.S., Howland R.H., Trivedi M.H., Zisook S., Jain R., McCracken J.T., Fava M., Iosifescu D., Greenwald S. Comparative effectiveness of biomarkers and clinical indicators for predicting outcomes of SSRI treatment in major depressive disorder: results of the BRITE-MD study. Psychiatry Res. 2009, 169:124-131.
37. Loosen P.T., Prange A.J. Serum thyrotropin response to thyrotropin-releasing hormone in psychiatric patients: a review. Am. J. Psychiatry 1982, 139:405-416.
38. Mokrani M.C., Duval F., Monreal Ortiz J., Champeval C., Maurice D., Macher J.P. Chronobiological HPT axis dysfunction in depression. Biol. Psychiatry 2006, 59:34S.
39. Nemeroff C.B., Evans D.L. Thyrotropin-releasing hormone (TRH), the thyroid axis, and affective disorder. Ann. N.Y. Acad. Sci. 1989, 553:304-310.
40. Nomura K., Castanon-Cervantes O., Davidson A., Fukuhara C. Selective serotonin reuptake inhibitors and raft inhibitors shorten the period of Period1-driven circadian bioluminescence rhythms in rat-1 fibroblasts. Life Sci. 2008, 82:1169-1174.
41. Papakostas G.I. Managing partial response or nonresponse: switching, augmentation, and combination strategies for major depressive disorder. J. Clin. Psychiatry 2009, 70:16-25.
42. Peteranderl C., Antonijevic I.A., Steiger A., Murck H., Held K., Frieboes R.M., Uhr M., Schaaf L. Nocturnal secretion of TSH and ACTH in male patients with depression and healthy controls. J. Psychiatr. Res. 2002, 36:189-196.
43. Piette F., Beck H. Perfusion intraveineuse lente de TRH: résultats chez les sujets normaux. Rev. Fr. Endocrinol. Clin. 1976, 17:513-521.
44. Quitkin F.M., McGrath P.J., Stewart J.W., Deliyannides D., Taylor B.P., Davies C.A., Klein D.F. Remission rates with 3 consecutive antidepressant trials: effectiveness for depressed outpatients. J. Clin. Psychiatry 2005, 66:670-676.
45. Rao M.L., Ruhrmann S., Retey B., Liappis N., Fuger J., Kraemer M., Kasper S., Möller H.J. Low plasma thyroid indices of depressed patients are attenuated by antidepressant drugs and influence treatment outcome. Pharmacopsychiatry 1996, 29:180-186.
46. Rush A.J. Limitations in efficacy of antidepressant monotherapy. J. Clin. Psychiatry 2007, 68:8-10.
47. Rush A.J., Wisniewski S.R., Warden D., Luther J.F., Davis L.L., Fava M., Nierenberg A.A., Trivedi M.H. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features. Arch. Gen. Psychiatry 2008, 65:870-880.
48. Souetre E., Salvati E., Pringuey D., Krebs B., Plasse Y., Darcourt G. The circadian rhythm of plasma thyrotropin in depression and recovery. Chronobiol. Int. 1986, 3:197-205.
49. Spitzer R.L., Endicott J. Schedule for Affective Disorders and Schizophrenia, Lifetime Version 1975, Biometric Research Division, New York State Psychiatric Institute, New York.
50. Sprouse J., Braselton J., Reynolds L. Fluoxetine modulates the circadian biological clock via phase advances of suprachiasmatic nucleus neuronal firing. Biol. Psychiatry 2006, 60:896-899.
51. Stassen H.H., Angst J., Hell D., Scharfetter C., Szegedi A. Is there a common resilience mechanism underlying antidepressant drug response? Evidence from 2848 patients. J. Clin. Psychiatry 2007, 68:1195-1205.